Cancer ResearchCancer Vaccine Trial Refines Its Target to KRAS Mutations
A completed early-stage trial enrolled 39 participants to evaluate a therapeutic cancer vaccine combined with treatment that helps immune cells attack tumors. The study included advanced lung, colorectal, pancreatic, and other cancers carrying relevant tumor mutations. Researchers assessed dosing, safety, immune responses, and early signs of cancer control. After initial trial data, they redesigned the vaccine, removing 16 of its original 20 mutation targets and focusing only on KRAS mutations. This is a vaccine intended to treat existing cancer, not prevent cancer in healthy adults. The supplied abstract does not report tumor responses, survival, or side effect rates, so it cannot establish whether the approach helps patients. Its main contribution here is documenting the vaccine's development and narrower targeting strategy, rather than demonstrating clinical benefit.
